Suppr超能文献

一种使用多激酶降解剂查询可降解激酶组的化学生物组学方法。

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

机构信息

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

出版信息

Cell Chem Biol. 2018 Jan 18;25(1):88-99.e6. doi: 10.1016/j.chembiol.2017.10.005. Epub 2017 Nov 9.

Abstract

Heterobifunctional molecules that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degradation represent an emerging pharmacological strategy. A major unanswered question is how generally applicable this strategy is to all protein targets. In this study, we designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quantitative proteomics to discover 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable. This set of kinases is only a fraction of the intracellular targets bound by the degrader, demonstrating that successful degradation requires more than target engagement. The results guided us to develop selective degraders for FLT3 and BTK, with potentials to improve disease treatment. Together, this study demonstrates an efficient approach to triage a gene family of interest to identify readily degradable targets for further studies and pre-clinical developments.

摘要

招募 E3 泛素连接酶(如 cereblon)进行靶向蛋白降解的杂双功能分子代表了一种新兴的药理学策略。一个尚未解决的主要问题是,这种策略在多大程度上适用于所有蛋白质靶标。在这项研究中,我们通过将一种高混杂的激酶抑制剂与 cereblon 结合配体连接,设计了一种多激酶降解剂,并使用定量蛋白质组学发现了 28 种激酶,包括 BTK、PTK2、PTK2B、FLT3、AURKA、AURKB、TEC、ULK1、ITK 和 CDK 家族的九个成员,这些激酶均可被降解。这组激酶只是该降解剂结合的细胞内靶标的一小部分,表明成功的降解需要的不仅仅是靶标结合。这些结果指导我们开发了针对 FLT3 和 BTK 的选择性降解剂,有可能改善疾病的治疗效果。总之,这项研究展示了一种有效的方法,可以对感兴趣的基因家族进行分类,以确定可进一步研究和临床前开发的易于降解的靶标。

相似文献

1
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.
Cell Chem Biol. 2018 Jan 18;25(1):88-99.e6. doi: 10.1016/j.chembiol.2017.10.005. Epub 2017 Nov 9.
2
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Bioorg Med Chem Lett. 2018 Sep 15;28(17):2939-2944. doi: 10.1016/j.bmcl.2018.07.008. Epub 2018 Jul 5.
3
Protein degradation through covalent inhibitor-based PROTACs.
Chem Commun (Camb). 2020 Feb 4;56(10):1521-1524. doi: 10.1039/c9cc08238g.
4
Quantitative Measurement of Rate of Targeted Protein Degradation.
ACS Chem Biol. 2024 Jul 19;19(7):1604-1615. doi: 10.1021/acschembio.4c00262. Epub 2024 Jul 9.
5
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.
ACS Chem Biol. 2019 Mar 15;14(3):342-347. doi: 10.1021/acschembio.8b01094. Epub 2019 Feb 27.
7
Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes.
Nat Chem Biol. 2021 Feb;17(2):152-160. doi: 10.1038/s41589-020-00686-2. Epub 2020 Nov 16.
8
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.
Cell. 2020 Dec 10;183(6):1714-1731.e10. doi: 10.1016/j.cell.2020.10.038. Epub 2020 Dec 3.
9
Delineating the role of cooperativity in the design of potent PROTACs for BTK.
Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7285-E7292. doi: 10.1073/pnas.1803662115. Epub 2018 Jul 16.
10
Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair.
Chembiochem. 2021 Jan 5;22(1):129-133. doi: 10.1002/cbic.202000527. Epub 2020 Oct 20.

引用本文的文献

1
Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review.
J Zhejiang Univ Sci B. 2025 Aug 25;26(8):713-739. doi: 10.1631/jzus.B2500021.
3
Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9.
Curr Res Chem Biol. 2021;1. doi: 10.1016/j.crchbi.2021.100008. Epub 2021 Aug 28.
4
FDA-approved kinase inhibitors in PROTAC design, development and synthesis.
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2542357. doi: 10.1080/14756366.2025.2542357. Epub 2025 Aug 12.
5
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs.
Commun Chem. 2025 Jul 29;8(1):218. doi: 10.1038/s42004-025-01598-9.
6
Unveiling the hidden interactome of CRBN molecular glues.
Nat Commun. 2025 Jul 24;16(1):6831. doi: 10.1038/s41467-025-62099-w.
7
Assessing the Suitability of Deubiquitylases As Substrates For Targeted Protein Degradation.
bioRxiv. 2025 Jun 14:2025.06.13.659525. doi: 10.1101/2025.06.13.659525.
8
SE(3)-equivariant ternary complex prediction towards target protein degradation.
Nat Commun. 2025 Jul 1;16(1):5514. doi: 10.1038/s41467-025-61272-5.
9
Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues.
NPJ Precis Oncol. 2025 Jun 28;9(1):204. doi: 10.1038/s41698-025-00931-8.
10
Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity.
ACS Omega. 2025 Jun 5;10(23):23926-23942. doi: 10.1021/acsomega.5c01241. eCollection 2025 Jun 17.

本文引用的文献

1
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Nat Chem Biol. 2018 Feb;14(2):163-170. doi: 10.1038/nchembio.2538. Epub 2017 Dec 18.
2
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.
Angew Chem Int Ed Engl. 2017 May 15;56(21):5738-5743. doi: 10.1002/anie.201611281. Epub 2017 Apr 18.
3
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.
Science. 2017 Apr 28;356(6336). doi: 10.1126/science.aal3755. Epub 2017 Mar 16.
4
Structural basis of PROTAC cooperative recognition for selective protein degradation.
Nat Chem Biol. 2017 May;13(5):514-521. doi: 10.1038/nchembio.2329. Epub 2017 Mar 13.
5
Transcription control by the ENL YEATS domain in acute leukaemia.
Nature. 2017 Mar 9;543(7644):270-274. doi: 10.1038/nature21688. Epub 2017 Mar 1.
7
A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Nature. 2016 Jul 14;535(7611):252-7. doi: 10.1038/nature18611. Epub 2016 Jun 22.
8
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9. doi: 10.1073/pnas.1521738113. Epub 2016 Jun 6.
9
Cul3-KLHL20 Ubiquitin Ligase Governs the Turnover of ULK1 and VPS34 Complexes to Control Autophagy Termination.
Mol Cell. 2016 Jan 7;61(1):84-97. doi: 10.1016/j.molcel.2015.11.001. Epub 2015 Dec 10.
10
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. doi: 10.1002/anie.201507634. Epub 2015 Nov 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验